| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Marketable securities | NaN | NaN | NaN | 7,939 |
| Cash and cash equivalents | 879,891 | 570,119 | 642,951 | 748,953 |
| Marketable securities | 60,295 | 17,363 | 2,991 | NaN |
| Accounts receivable, net | 205,226 | 139,444 | 116,518 | 76,868 |
| Inventories | 32,980 | 26,753 | 24,527 | 18,277 |
| Prepaid expenses and other current assets | 62,914 | 44,070 | 52,395 | 60,240 |
| Total current assets | 1,241,306 | 797,749 | 839,382 | 912,277 |
| Investment in nonconsolidated entities | NaN | NaN | 92,168 | 108,002 |
| Equity method investments | 61,529 | 79,972 | NaN | NaN |
| Property and equipment, net | 4,941 | 5,366 | 5,830 | 6,107 |
| Operating lease right-of-use assets | 17,226 | 8,149 | 6,553 | 6,186 |
| Intangible assets, net | 27,359 | 28,077 | 28,795 | 29,513 |
| Other assets | 18,620 | 16,712 | 25,522 | 18,105 |
| Total assets | 1,370,981 | 936,025 | 998,250 | 1,080,190 |
| Deferred revenue, current portion | NaN | NaN | NaN | 10,540 |
| Accounts payable | 29,058 | 36,228 | 18,702 | 26,134 |
| Accrued compensation and benefits | 39,338 | 76,703 | 56,155 | 37,187 |
| Accrued research and development liabilities | 54,430 | 41,436 | 34,619 | 31,295 |
| Operating lease liabilities, current portion | 4,439 | 6,192 | 5,294 | 4,782 |
| Deferred revenue, current portion | 6,115 | 7,190 | 9,087 | NaN |
| 2027 notes, net | 547,483 | NaN | NaN | NaN |
| Accrued rebates and other related costs | 59,784 | NaN | NaN | NaN |
| Accrued commercial | 36,963 | NaN | NaN | NaN |
| Deferred royalty obligations, current portion | 21,488 | NaN | NaN | NaN |
| Accrued professional services | 7,540 | NaN | NaN | NaN |
| Accrued interest | 5,188 | NaN | NaN | NaN |
| Other accrued liabilities | 4,546 | NaN | NaN | NaN |
| Other current liabilities | 135,509 | 120,222 | 92,743 | 65,916 |
| Total current liabilities | 816,372 | 287,971 | 216,600 | 175,854 |
| 2033 notes, 2031 notes, 2029 notes, and 2027 notes-A2033Convertible Senior Notes | 619,631 | NaN | NaN | NaN |
| 2033 notes, 2031 notes, 2029 notes, and 2027 notes-A2031Convertible Senior Notes | 565,045 | 564,565 | 564,087 | NaN |
| 2033 notes, 2031 notes, 2029 notes, and 2027 notes-A2029Convertible Senior Notes | 741,402 | 740,890 | 740,380 | NaN |
| 2033 notes, 2031 notes, 2029 notes, and 2027 notes-A2027Convertible Senior Notes | 0 | 547,015 | 546,549 | NaN |
| 2031 notes, 2029 notes, 2027 notes, and term loan, net-Term Loan | NaN | 0 | 0 | NaN |
| Carrying value of deferred royalty obligations, net | 905,336 | 891,388 | 868,059 | NaN |
| Funding Agreement | 19,281 | 21,439 | 30,029 | NaN |
| Royalty Purchase Agreement | 0 | 0 | 0 | NaN |
| Fair value of embedded derivative liability | 19,281 | 21,439 | 30,029 | NaN |
| Unamortized debt discount and issuance costs | 53,432 | 57,797 | 61,962 | NaN |
| Deferred royalty obligations, net | 871,185 | 855,030 | 836,126 | 813,959 |
| Operating lease liabilities, net of current portion | 14,216 | 3,811 | 3,427 | 4,025 |
| Term loan, net | NaN | NaN | NaN | 0 |
| Deferred revenue, net of current portion | NaN | NaN | NaN | 14,667 |
| Notes, net-Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine | NaN | NaN | NaN | 739,874 |
| Notes, net-Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven | NaN | NaN | NaN | 546,088 |
| Deferred revenue, net of current portion | 11,776 | 13,080 | 13,131 | NaN |
| Notes, net-One Point Seven Five Percentage Convertible Senior Notes Due Two Thousand And Thirty One | NaN | NaN | NaN | 563,597 |
| Other long-term liabilities | 229 | 244 | 679 | 545 |
| Total liabilities | 3,639,856 | 3,012,606 | 2,920,979 | 2,858,609 |
| Redeemable convertible noncontrolling interests | -951 | -570 | 23 | -445 |
| Common stock, 0.001 par value 500,000,000 shares authorized 198,759,831 shares issued and 192,633,286 shares outstanding as of march 31, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of december 31, 2025 | 204 | 202 | 200 | 198 |
| Treasury stock, at cost 7,597,172 shares as of march 31, 2026 7,597,172 shares as of december 31, 2025 | 405,776 | 323,276 | 323,276 | NaN |
| Additional paid-in capital | 2,112,454 | 2,057,646 | 2,018,335 | 1,980,805 |
| Treasury stock, at cost 7,597,172 shares as of june 30, 2025 6,191,761 shares as of december 31, 2024 | NaN | NaN | NaN | 323,276 |
| Accumulated other comprehensive income (loss) | -8 | 12 | 2 | 1 |
| Accumulated deficit | -3,985,237 | -3,821,194 | -3,628,331 | -3,445,588 |
| Total bridgebio stockholders deficit | -2,278,363 | -2,086,610 | -1,933,070 | -1,787,860 |
| Noncontrolling interests | 10,439 | 10,599 | 10,318 | 9,886 |
| Total stockholders deficit | -2,267,924 | -2,076,011 | -1,922,752 | -1,777,974 |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit | 1,370,981 | 936,025 | 998,250 | 1,080,190 |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)